Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 12, December, p. 1643–1650

doi: 10.17219/acem/75775

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The effect of anakinra to nephrotoxicity with cisplatin induced in rats: Biochemical, gene expression and histopathological evaluation

Adalet Ozcicek1,A,B,D,F, Fatih Ozcicek1,B,E,F, Ferda Keskin Cimen2,C,F, Renad Mammadov3,B,F, Murat Cankaya4,C,F, Talat Ezmeci5,E,F, Durdu Altuner3,A,D,F

1 Department of Internal Medicine, Faculty of Medicine, Erzincan University, Turkey

2 Department of Pathology, Faculty of Medicine, Erzincan University, Turkey

3 Department of Pharmacology, Faculty of Medicine, Erzincan University, Turkey

4 Department of Biology, Arts and Sciences, Erzincan University, Turkey

5 Department of Public Health, Faculty of Medicine, Erzincan University, Turkey

Abstract

Background. Oxidative stress and interleukin-1 beta (IL-1β) have been reported to play a role in the pathogenesis of nephrotoxicity induced by cisplatin.
Objectives. The objective of this study was to investigate the effect of anakinra, which is an IL-1β receptor antagonist, on cisplatin-induced nephrotoxicity in rats, through biochemical, gene expression and histopathological analyses.
Material and Methods. The study was designed with 4 groups. For 1 week, the control group (C) and the cisplatin (Cis) group received distilled water, while the cisplatin + anakinra 50 (Cis + ANA50) group and the cisplatin + anakinra 100 (Cis + ANA100) group were intraperitoneally administered 50 mg/kg and 100 mg/kg of anakinra, respectively. The Cis, Cis + ANA50 and Cis + ANA100 groups were intraperitoneally injected with a 2.5 mg/kg dose of cisplatin for 7 days. After sacrifice, the kidney tissue of each rat was extracted for the assessment of the malondialdehyde (MDA) and total glutathione (tGSH) levels, and for gene expression analyses of IL-1β. The kidney tissues were histopathologically evaluated. Statistical analyses of the data were performed using one-way analysis of variance (ANOVA).
Results. The administration of cisplatin (the Cis group) yielded a higher level of MDA (4.75 ±0.25 nmol/mL; p < 0.001) and lower levels of tGSH (1.80 ±0.35 mg/L; p < 0.001) compared to other groups. Cisplatin also increased IL-1β gene expression (6.33 ±0.27 gene expression levels; p < 0.001) compared to other groups. The impact of anakinra on the MDA and tGSH levels, and on IL-1β gene expression induced by cisplatin was observed as a reversal of these findings (p < 0.05). Anakinra better prevented an increase of the levels of MDA and IL-1β at a dose of 100 mg/kg compared to a 50 mg/kg dose.
Conclusion. Anakinra prevents oxidative kidney damage induced by cisplatin, in a dose-dependent manner. This result suggests that anakinra may be useful in the treatment of cisplatin-induced kidney damage.

Key words

rats, cisplatin-nephrotoxicity, anakinra

References (27)

  1. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: A historical perspective and an update. Eur J Cancer. 1998;34(10):1522–1534.
  2. Hartshorn EA, Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother. 1993;27(12):1519–1525.
  3. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med. 2003;142(3):178–186.
  4. Fouad AA, Morsy MA, Gomaa W. Protective effect of carnosine against cisplatin-induced nephrotoxicity in mice. Environ Toxicol Pharmacol. 2008;25(3):292–297.
  5. Özen S, Akyol Ö, Iraz M, et al. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin‐induced nephrotoxicity in rats. J Appl Toxicol. 2004;24(1):27–35.
  6. Zirak MR, Rahimian R, Ghazi-Khansari M, et al. Tropisetron attenuates cisplatin-induced nephrotoxicity in mice. Eur J Pharmacol. 2014;738:222–229.
  7. Cvetkovic RS, Keating G. Anakinra. BioDrugs. 2002;16(4):303–311.
  8. Hasturk AE, Yilmaz ER, Turkoglu E, et al. Potential neuroprotective effect of Anakinra in spinal cord injury in an in vivo experimental animal model. Neuroscience. 2015;20(2):124.
  9. Askin Esen Hasturk M, Yilmaz ER, Turkoglu E, et al. Therapeutic evaluation of interleukin-1 beta antagonist Anakinra against traumatic brain injury in rats. Ulus Travma Acil Cerrahi Derg. 2015;21(1):1–8.
  10. Nayki UA, Nayki C, Cetin N, et al. Effect of Kineret® on ovarian ischemia reperfusion injury in a rat model. J Obstet Gynaecol Res. 2016;42(11):1525–1533.
  11. Kuyrukluyıldız U, Küpeli İ, Bedir Z, et al. The effect of anakinra on paclitaxel-induced peripheral neuropathic pain in rats. Turk J Anaesthesiol Reanim. 2016;44(6):287.
  12. Coskun R, Turan MI, Turan IS, Gulapoglu M. The protective effect of thiamine pyrophosphate, but not thiamine, against cardiotoxicity induced with cisplatin in rats. Drug Chem Toxicol. 2014;37(3):290–294.
  13. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–358.
  14. Sedlak J, Lindsay RH. Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem. 1968;25:192–205.
  15. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34(3):497–500.
  16. Peres LAB, Cunha AD Jr. Acute nephrotoxicity of cisplatin: Molecular mechanisms. J Bras Nefrol. 2013;35(4):332–340.
  17. Parlakpinar H, Sahna E, Ozer M, Ozugurlu F, Vardi N, Acet A. Physiological and pharmacological concentrations of melatonin protect against cisplatin‐induced acute renal injury. J Pineal Res. 2002;33(3):161–166.
  18. Girotti AW. Lipid hydroperoxide generation, turnover and effector action in biological systems. J Lipid Res. 1998;39(8):1529–1542.
  19. Kilic U, Kilic E, Tuzcu Z, et al. Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab. 2013;10(1):7.
  20. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503–508.
  21. Youssef Nasr A, Al Shahat Ibrahim A. Aged garlic extract ameliorates the oxidative stress, histomorphological and ultrastructural changes of cisplatin‐induced nephrotoxicity in adult male rats. Microsc Res Tech. 2015;78(6):452–461.
  22. Boroushaki MT, Rajabian A, Farzadnia M, et al. Protective effect of pomegranate seed oil against cisplatin-induced nephrotoxicity in rat. Ren Fail. 2015;37(8):1338–1343.
  23. Alfieri AB, Cubeddu LX. Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn Schmiedebergs Arch Pharmacol. 2000;361(3):334–338.
  24. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.
  25. Kisaoglu A, Borekci B, Yapca OE, Bilen H, Suleyman H. Tissue damage and oxidant/antioxidant balance. Eurasian J Med. 2013;45(1):47.
  26. Noori S, Mahboob T. Antioxidant effect of carnosine pretreatment on cisplatin-induced renal oxidative stress in rats. Indian J Clin Biochem. 2010;25(1):86–91.
  27. Karakoc H, Altintas R, Parlakpinar H, et al. Protective effects of molsidomine against cisplatin-induced nephrotoxicity. Adv Clin Exp Med. 2014;24(4):585–593.
© Wroclaw Medical University